Abstract: Patients with end-stage renal disease have increased plasma concentrations of statins, which is a risk factor for rhabdomyolysis, as well as elevated levels of uremic toxins (UTs). We investigated the effects of uremic serum residue and UTs on organic anion-transporting peptide (OATP1B1)-and OATP1B3-mediated pravastatin uptake. We evaluated the effects of normal serum residue with four UTs (hippuric acid, 3-carboxy-4-methyl-5-propyl-2-furan propionate, indole-3-acetic acid, and 3-indoxyl sulfate) and uremic serum residue on pravastatin uptake by OATP1B1-or OATP1B3-expressing HEK293 cells. Furthermore, we assessed the contribution of each transporter using cryopreserved human hepatocytes. Uremic serum residue and UTs significantly inhibited OATP1B1-mediated pravastatin uptake. Uremic serum residue accelerated OATP1B3-mediated pravastatin uptake, while UTs had no effect. There was no difference in pravastatin uptake between uremic-and normal serum residue-treated hepatocytes. The results suggest that the effects of uremic serum on pravastatin hepatic uptake may be considered negligible in end-stage renal disease patients.
End-stage renal disease (ESRD) is the last stage of chronic kidney disease (CKD) in which dialysis or transplantation is required to compensate for the loss of kidney function. The prevalence and mortality of cardiovascular and cerebrovascular disorders are much higher in ESRD patients (1) . On the other hand, lipid metabolism disorders constitute a risk factor for cardiovascular and cerebrovascular disorders and an aggravating factor in kidney disease. Thus, their prevention is important in CKD patients (2) .
Statins, which are 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors, are a class of drugs that help lower blood cholesterol levels. Though statins do not lower all-cause mortality or improve the glomerular filtration rate in CKD patients (3) , atorvastatin has been reported to reduce the risk of developing coronary artery disease in patients with kidney dysfunction (4) . Therefore, statins are frequently employed to treat lipid metabolism disorders in CKD patients.
Rhabdomyolysis is the most common serious adverse reaction in statin users, and kidney dysfunction has been reported as a risk factor for the development of rhabdomyolysis (5) . We previously reported that accumulated uremic toxins (UTs) and trace element deficiency in ESRD patients enhance the toxicity of statins against differentiated human rhabdomyosarcoma cells (6, 7) . In addition to kidney dysfunction, there are ESRD-specific conditions, such as accumulated UTs, that may be associated with statin-induced rhabdomyolysis. The plasma concentration of atorvastatin metabolites is higher in patients with atorvastatin-induced myopathy than in healthy control subjects (8) . Furthermore, plasma lovastatin is elevated in patients with kidney dysfunction compared to patients with normal kidney function (9) . Therefore, elevated plasma concentrations of statin and its metabolites might contribute to statin-induced rhabdomyolysis in ESRD patients.
The uptake of statins into hepatocytes is mediated by two organic anion-transporting polypeptides (OATPs), OATP1B1 and OATP1B3 (also known as SLCO1B1 and SLCO1B3, respectively), which are expressed on the sinusoidal membrane of these cells (10) . Because previous reports linked mutations in these two genes with reduced transport activity of statins, we hypothesized that the activities of OATPs in ESRD patients may be lower than those in patients with normal kidney function (11, 12) .
Decreased kidney function leads to an accumulation of protein-bound UTs, such as hippuric acid (HA), 3-carboxy-4-methyl-5-propyl-2-furan propionate (CMPF), indole-3-acetic acid (IAA), and 3-indoxyl sulfate (IS), which cannot be effectively removed by conventional hemodialysis in ESRD patients (13) . It has been reported that IS and CMPF, which are highly concentrated in clinical cases, inhibit OATP1B1-and OATP1B3-mediated uptake of their substrates (14, 15) . Thus, serum obtained from ESRD patients (uremic serum), which is expected to contain high concentrations of UTs, may inhibit uptake mediated by both transporters.
In the present study, to clarify the effects of uremic serum on the hepatic uptake of pravastatin, we examined the effects of uremic serum and specific UTs on OATP1B1-and OATP1B3-mediated pravastatin uptake into OATP-expressing HEK293 cells and cryopreserved human hepatocytes.
MATERIALS AND METHODS

Reagents
Pravastatin was purchased from Tokyo Chemical Industry (Tokyo, Japan); IAA, IS, non-essential amino-acid solution, penicillin-streptomycin mixed solution, and G418 from Nacalai Tesque (Kyoto, Japan); CMPF from Cayman Chemical Company (Ann Arbor, MI, USA), HA from Sigma-Aldrich (St. Louis, MO, USA); methyl 4-hydroxybenzoate from Wako Pure Chemical Industries (Osaka, Japan); losartan potassium from LKT Laboratories (St. Paul, MN, USA); normal serum from MerckMillipore (Billerica, MA, USA). All other chemicals were of analytical grade. Pooled uremic sera were obtained from more than 400 dialysis patients in Shirasagi Hospital (Osaka, Japan). All patients enrolled in this study were patients with stage 5 CKD undergoing hemodialysis, with serum creatinine ≥6 mg/dL and estimated glomerular filtration rate < 10 mL/min. The pooled uremic serum contained 164 μM IS, 209 μM HA, 13 μM IAA, and 96 μM CMPF. This study was approved by the Shirasagi Hospital and Kyoto Pharmaceutical University ethical review boards on 11 December 2008 (IRB number J2012013) and 1 April 2008 (IRB number 08-04), respectively.
Cell culture
Human embryonic kidney (HEK)293 cells transduced with OATP1B1 (HEK293-OATP1B1) or empty vector (HEK293-Mock) were previously established (16) . HEK293 transduced with OATP1B3 (HEK293-OATP1B3) were kindly provided by Professor H. Kusuhara and Lecturer K. Maeda (Tokyo University, Japan) (17) .
Test solutions
To create 10% deproteinized normal (normal serum residue; NSR) or uremic serum (uremic serum residue; USR), sera were first deproteinized by treatment with three volumes of methanol. After centrifugation (1630 × g, 30 min), supernatants were collected and dried under a stream of nitrogen at 50 C. Residues were reconstituted in 10 volumes of HEPES-buffered Hanks' balanced salt solution (HEPES-HBSS; 137 mM NaCl, 5.4 mM KCl, 1.3 mM CaCl 2 , 0.4 mM MgSO 4 , 0.5 mM MgCl 2, 0.3 mM Na 2 HPO 4 , 0.4 mM KH 2 PO 4, 4.2 mM NaHCO 3 , 5.6 mM glucose and 25.0 mM HEPES at pH 7.4 adjusted with 1 M NaOH), followed by ultrafiltration through 0.22-μm membrane filters.
UT solutions were prepared in 10% NSRcontaining HEPES-HBSS at concentrations (10 μM CMPF, 21 μM HA, 1.3 μM IAA, and 16 μM IS) that we determined to correspond to those in 10% USR by high-performance liquid chromatography (HPLC). Pravastatin was used at a final concentration of 30-500 μM in uptake studies in HEK293-OATP1B1 and HEK293-OATP1B3 cells, and at a concentration of 8 μM, intended for a range of clinical settings, in uptake studies in human hepatocytes.
Pravastatin uptake into transfected cells
Cells (0.8 × 10 5 /well) were seeded in 24-well plates coated with type I collagen, incubated for 3 days at 37 C with 5% CO 2 , and then exposed to 5 mM NaBu for 1 day to increase transporter protein expression (18) . Cells were washed twice with pre-warmed HEPES-HBSS and incubated, first with HEPES-HBSS for 10 min and then with each test solution (300 μL) at 37 C for 10 (for HEK293-OATP1B3) or 30 min (HEK293-OATP1B1) as steady-state uptake. The cells were washed with 0.5 mL (1×) and 1 mL (2×) of ice-cold PBS (0.9 mM CaCl 2 , 0.9 mM MgCl 2 , 137 mM NaCl, 5.4 mM KCl, and 1.5 mM KH 2 PO 4 ) and subjected to HPLC. Protein concentration was measured by the Lowry method (19) . OATP1B1-and OATP1B3-mediated uptake was quantified by subtracting the uptake in HEK-Mock from that in HEK293-OATP1B1 and HEK293-OATP1B3, respectively.
Pravastatin uptake into human hepatocytes
Cryopreserved human hepatocytes (viability > 98.7%) were purchased from XenoTech (Kansas City, KS, USA). Cells were thawed using the OptiThaw kit (XenoTech) according to the manufacturer's protocol. Briefly, the hepatocyte suspension was thawed at 37 C in an OptiThaw tube, transferred to 1.5 mL OptiThaw medium, and centrifuged (100 × g, 5 min, RT). After the removal of the supernatant, the cells were re-suspended in OptiPlate medium (XenoTech) at 1.3 × 10 6 cells/ well and transferred to 48-well Celltight C-1 plates (Sumitomo Bakelite, Tokyo, Japan) at 200 μL/well. After 5 h at 37 C, the medium was removed and the cells were washed once with 0.5 mL pre-warmed HEPES-HBSS. Subsequently, the cells were incubated at 37 C, first for 15 min with 200 μL HEPES-HBSS and then with 8 μM pravastatin (200 μL in HEPES-HBSS with 10% USR or NSR) at 37 C for 5 min. The cells were washed three times with 0.5 mL of ice-cold PBS for liquid chromatographytandem mass spectrometry (LC-MS/MS).
HPLC and LC-MS/MS for pravastatin quantification
Pravastatin levels in HEK293 cells and hepatocytes were measured by HPLC and LC-MS/MS, respectively. Samples were dissolved in 0.3 M NaOH (400 μL for HPLC and 120 μL for LC-MS/ MS) and neutralized with 0.3 M phosphate buffer (pH 5.2, 600 and 120 μL for HPLC and LC-MS/ MS, respectively). For HPLC, we added 50 μL of methyl 4-hydroxybenzoate (750 ng/mL in methanol) as internal standard and 3.65 mL of diluent (methanol or acetonitrile) to 900 μL of cell lysate. For LC-MS/MS, we added 100 μL of losartan potassium (17.6 ng/mL in methanol) as an internal standard and 900 μL of acetonitrile to 300 μL of cell lysate. After centrifugation (1630 × g, 30 min), supernatants were dried at 40-50 C under a nitrogen stream.
For HPLC, residues were reconstituted in 150 μL of 20 mM sodium citrate (pH 3.2)/acetonitrile [72:28] and analyzed using a HPLC system equipped with a LC-10AS pump, an SPD-6A UV detector, a SIL-9A injector, and a C-R4A integrator (Shimadzu, Kyoto, Japan). We used an Inertsil ODS-3 column (4.0 × 250 mm; GL Sciences, Tokyo, Japan) kept at 40 C, and applied reconstitution buffer as the mobile phase at 1.0 mL/min. Pravastatin and methyl 4-hydroxybenzoate acid were monitored at 239 nm and eluted at 21 and 11 min, respectively.
For LC-MS/MS, residues were reconstituted in 150 μL of water/acetonitrile [1:1] . A prominence UFLC chromatographic system (Shimadzu) was coupled to a mass spectrometer (API5000; AB SCIEX, Ontario, Canada) and used in negative ionization mode. We used a CAPCELL PAK C18 MG II column (5 μm, 4.6 × 150 mm; Shiseido, Tokyo, Japan) kept at 40 C, with 10 mM ammonium acetate/methanol [2:3] as the mobile phase at 0.5 mL/ min. MS/MS was operated in multiple-reaction monitoring mode and the transitions monitored were m/z 423 to 321 (pravastatin) and m/z 421 to 127 (losartan).
Statistical analysis
Data are expressed as the mean AE standard error (SE). Significant differences between groups were determined using unpaired Student's t-tests. Multiple comparisons were analyzed by non-repeated measures analysis of variance (ANOVA) with subsequent Tukey-Kramer or Dunnett's multiple comparison tests. A P value < 0.05 was considered significant.
RESULTS
Effect of uremic serum on pravastatin uptake into HEK293-OATP1B1 cells
We evaluated the effect of uremic serum on OATP1B1-mediated uptake of pravastatin by treating HEK293-OATP1B1 cells with various concentrations of pravastatin (30, 100, 300, and 500 μM) in the presence of 10% NSR or USR. At all concentrations, uptake into 10% USR-treated cells was significantly lower than that into 10% NSR-treated cells (Fig. 1) .
Effects of uremic toxins on pravastatin uptake into HEK293-OATP1B1 cells
We assessed the effects of four UTs reportedly present in uremic serum (IS, HA, CMPF, and IAA), using them at concentrations similar to those found in 10% uremic serum. At a low pravastatin concentration (30 μM), IS significantly inhibited OATP1B1-mediated uptake of pravastatin, similarly to 10% USR (Fig. 2a) . However, unlike USR, it did not inhibit the uptake of pravastatin at the high concentration of 300 μM (Fig. 2b ). CMPF and IAA had similar effects: they inhibited the uptake of pravastatin at 30 μM but not at 300 μM (Fig. 3a and b) . Conversely, HA significantly inhibited the uptake of pravastatin at 300 μM, but not at 30 μM (Fig. 3b) .
Effects of uremic serum on pravastatin uptake into HEK293-OATP1B3 cells
Next, we examined the effects of 10% USR on OATP1B3-mediated pravastatin transport. As shown in Figure 4 , pravastatin uptake was significantly higher in the USR than in the NSR-treated HEK293-OATP1B3 cells at certain pravastatin concentrations (60, 100, and 200 μM).
Effects of uremic toxins on pravastatin uptake into HEK293-OATP1B3 cells
In contrast to the USR, none of the four tested UTs (IS, HA, CMPF, and IAA) nor a mixture containing all of them affected OATP1B3-mediated uptake of pravastatin at the tested pravastatin concentration (60 μM) (Fig. 5) .
Effects of uremic serum on pravastatin uptake into human hepatocytes
To assess whether the witnessed effects of USR on OATP-mediated pravastatin are also in effect in vivo, we compared the uptake of pravastatin into human hepatocytes in the presence of 10% USR or NSR. Interestingly, both NSR and USR significantly decreased the uptake of pravastatin at 8 μM compared to the serum residue-non-treated controls. However, there was no difference in the uptake of 8 μM pravastatin between the two serum residue types (Fig. 6) .
DISCUSSION
This study showed that USR significantly decreased pravastatin uptake into OATP1B1-expressing cells compared to NSR (Fig. 1) , indicating the presence of inhibitors of OATP1B1-mediated pravastatin uptake in USR. We hypothesized that IS, HA, CMPF, and IAA might cooperatively inhibit OATP1B1-mediated uptake of pravastatin because a mixture of these UTs at clinically relevant concentrations reportedly inhibited OATP1B1-mediated SN-38 uptake (15, 20) . We found that IS, CMPF, and IAA inhibited OATP1B1-mediated uptake of pravastatin at 30 μM, but not at 300 μM, whereas HA showed an opposite effect (Figs 2 and 3) . Our results are similar to those of Bachmakov et al. (2008) , who reported that FIG. 1 . Effects of 10% NSR or 10% USR on the OATP1B1-mediated uptake of pravastatin into HEK293 cells. Uptake experiment of pravastatin was assessed in HEPES-HBSS containing pravastatin (30, 100, 300, 500 μM) in the presence of 10% NSR (open circles) or 10% USR (closed circles). Data represent the mean AE SE (n = 3-4). The difference between uptake in 10% NSR-and 10% USR-treated cells was determined by unpaired Student's t-test (*P < 0.05). NSR: normal serum residue; USR: uremic serum residue.
FIG. 2.
Effect of indoxyl sulfate on the OATP1B1-mediated uptake of pravastatin into HEK293 cells. OATP1B1-mediated uptake of pravastatin at 30 μM (a) and 300 μM (b) was assessed in the presence of 10% NSR, 10% NSR + IS (16 μM) or 10% USR. Data represent the mean AE SE (n = 3-4). Differences from NSR were determined by ANOVA followed by Dunnett's test (**P < 0.01 vs. NSR). NSR: normal serum residue; USR: uremic serum residue. rosiglitazone at high concentration can inhibit OATP1B1-mediated pravastatin uptake, while rosiglitazone at low concentration has an activating effect (21) . Therefore, our data clearly suggest that OATP1B1 has a high-affinity/low-capacity site sensitive to IS, CMPF, and IAA, and a low-affinity/highcapacity site sensitive to HA. In a clinical setting, IS, CMPF, and IAA may be able to inhibit OATP1B1-mediated transport of pravastatin because the plasma concentration of pravastatin is not sufficiently high to saturate the high-affinity site.
Opposite to its effect on OATP1B1-mediated transport, USR significantly increased the uptake of pravastatin (at 60 μM and 300 μM pravastatin) into OATP1B3-expressing cells compared to NSR (Fig. 4) . Because OATP1B3-mediated uptake of pravastatin into NSR-treated cells was lower than that into serum-non-treated cells (see Appendix S1, Supporting Information), compounds that inhibit OATP1B3-mediated uptake of pravastatin may be contained in NSR. Therefore, it is possible that USR lacks the compounds contained in NSR or contains compounds that enhance the transport activity of OATP1B3. It has been reported that ibuprofen activates OATP1B1-and OATP1B3-mediated uptake of pravastatin through an allosteric effect triggered at a relatively high concentration (50 μM) of ibuprofen (22) . Similarly, rosiglitazone at high concentration can inhibit OATP1B3-mediated pravastatin uptake, while activation is observed when it is used at low concentration (21). Hence, it is possible that USR components also activate OATP1B3-mediated pravastatin uptake via an allosteric mechanism.
FIG. 3.
Effect of uremic toxins on OATP1B1-mediated uptake of pravastatin into HEK293 cells. OATP1B1-mediated uptake of pravastatin at 30 μM (a) and 300 μM (b) was assessed in the presence of 10% NSR, 10% NSR + uremic toxin (HA 21 μM, CMPF 10 μM, IAA 1.3 μM) or 10% USR. Data represent the mean AE SE (n = 7-12). Differences from NSR were determined by ANOVA followed by Dunnett's test (*P < 0.05, **P < 0.01 vs. NSR). NSR: normal serum residue; USR: uremic serum residue.
FIG. 4.
Effects of 10% NSR or USR on the OATP1B3-mediated uptake into HEK293 cells. Uptake of pravastatin was assessed in HEPES-HBSS containing pravastatin (30, 60, 100, 200, 300 μM) in the presence of 10% NSR (open circles) or 10% USR (closed circles). Data represent the mean AE SE (n = 3-4). The difference between uptake in 10% NSR-and 10% USR-treated cells was determined by unpaired Student's ttest (*P < 0.05). NSR: normal serum residue; USR: uremic serum residue.
FIG. 5.
Effect of each UT or the mixture of four UTs with 10% NSR on OATP1B3-mediated uptake of pravastatin into HEK293 cells. OATP1B3-mediated uptake of pravastatin at 60 μM was assessed in the presence of 10% NSR without or with UT (IS 16 μM, HA 21 μM, CMPF 10 μM, IAA 1.3 μM or the mixture of four UTs) or 10% USR. Data represent the mean AE SE (n = 6-16). Differences from NSR were determined by ANOVA followed by Dunnett's test (**P < 0.05 vs. NSR). NSR: normal serum residue; UT: uremic toxin; USR: uremic serum residue.
FIG. 6.
Effect of 10% NSR or USR on pravastatin uptake in human hepatocytes. Uptake of 8 μM pravastatin in the presence of no serum residue (Control), 10% NSR or 10% USR. Data represent the mean AE SE (n = 7). Differences were determined by Tukey-Kramer test (**P < 0.01 vs. control). NSR: normal serum residue; UT: uremic toxin; USR: uremic serum residue.
The four tested UTs did not affect OATP1B3-mediated pravastatin uptake (Fig. 5) . Thus, the activatory effect may not be exerted by a UT but rather result from abnormal levels of other endogenous compounds that are substrates of OATP1B3 in ESRD patients. For example, bilirubin is a substrate for OATP1B3, and its serum levels significantly decrease as kidney function declines (23) . It has been reported that unconjugated bilirubin inhibits the OATP1B3-mediated uptake of 17β-Dglucuronosyl oestradiol, a typical substrate of OATP1B3 (24) . Thus, low serum bilirubin might cause an apparent activation of OATP1B3-mediated pravastatin uptake.
In addition, we assessed the contribution of these two transporters to pravastatin uptake into the liver by using human hepatocytes. The uptake of pravastatin (8 μM) by human hepatocytes treated with NSR and USR was similar, but it was significantly lower than that by serum residue-non-treated cells (Fig. 6) . In other words, the results in human hepatocytes were different from those observed in OATP1B1-and OATP-1B3-mediated uptake, which made us suspect inhibition by serum components. The affinity of OATP1B1 for pravastatin (Km = 104 μM) is higher than that of OATP1B3 (Km = 228 μM) (22) . In addition, the expression level of OATP1B1 protein is 45 times higher than that of OATP1B3, and the contribution of OATP1B1 and OATP1B3 to hepatic uptake of pravastatin is above 60% and below 10%, respectively (10) . Because it has been reported that OATP1B1 and OATP1B3 are down-regulated at equal rates in ESRD patients (15) , the contribution of OATP1B1 and OATP1B3 to hepatic uptake of pravastatin does not change. Hence, it is thought that OATP1B1 has a larger contribution to pravastatin uptake into hepatocytes than OATP1B3 in ESRD patients. That is to say, the results in human hepatocytes were expected to be similar to those in OATP1B1-mediated uptake. However, differences between USR and NSR with respect to their effects on OATP-mediated pravastatin transport did not manifest. Therefore, the results might suggest the involvement of other transporters, such as OATP2B1, which plays a role in hepatic pravastatin uptake and exhibits pH-sensitive transport activity for pravastatin (25) . Because the expression of OATP1B1 and 1B3 mRNA is decreased by treatment with USR for 24 h (26), another possibility is that longer treatment time of USR might have an effect on hepatic pravastatin uptake through variable expression of OATP1B1 and 1B3. Moreover, the elevated plasma statin concentrations in ESRD patients may result from UT-induced changes in intestinal secretion rather than hepatic uptake, as non-renal clearance of pravastatin was partly induced by down-regulation of intestinal multidrug resistance-related protein 2 by UTs (26) . Therefore, further research will be required to reveal whether elevated plasma concentrations of statins actually increase the risk of statin-induced rhabdomyolysis in ESRD patients.
CONCLUSIONS
We demonstrated for the first time that uremic serum residue inhibits OATP1B1-mediated and activates OATP1B3-mediated pravastatin uptake, and showed that the inhibitory effect is, at least partly, associated with specific UTs. Moreover, we showed that USR does not change the uptake of pravastatin into human hepatocytes compared to normal serum residue, suggesting that the aforementioned differences between the two serum residues with respect to OATP1B1-and OATP1B3-mediated pravastatin uptake have negligible effects on uptake into hepatocytes. However, there is no doubt that the risk of myopathy in statin treatment is increased in ESRD patients, so it is important to carefully evaluate creatine kinase level in these patients. However, plasma statin is elevated by a decrease in the intestinal secretion, and the contribution of other hepatic transporters in ESRD patients remains unclear. Therefore, further research is required to guide appropriate use of statins in CKD and ESRD patients.
